A PYMNTS Company

Denmark: After EU fines, H. Lundbeck faces new probe

By  |  January 26, 2014

Pharmaceutical giant H. Lundbeck was fined by the European Commission just last year for a pay-for-delay scheme, but now the company is facing antitrust scrutiny from its home country of Denmark.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say H. Lundbeck, which was fined last year by the Commission for paying to have a generic form of its antidepressant Celexa from entering the market, is now under fire by various healthcare providers seeking counsel by the attorney general over whether they can pursue claims against the firm.

    This time, say reports, H. Lundbeck is in a spat with generic drug maker Actavis regarding the antidepressant Cipralex. While Actavis argues H. Lundbeck is hampering competition, H. Lundbeck is accusing Actavis of violating its patents.

    The feud comes after European Commission fined H. Lundbeck nearly $200 million for the so-called pay-for-delay scheme in 2013.

    Full Content: Fierce Pharma

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.